Senores Pharmaceuticals · NSE: SENORES · BSE: 544319
Q3 FY25 results · Oct–Dec 2024
Senores Pharmaceuticals reported revenue from operations of ₹103.02 crore and net profit of ₹16.43 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 103.02 | — | — | — | — |
| Other income | 5.16 | — | — | — | — |
| Total income | 108.17 | — | — | — | — |
| Profit before tax | 20.48 | — | — | — | — |
| Net profit for the period | 16.43 | — | — | — | — |
| Attributable to shareholders of the company | 17.18 | — | — | — | — |
| EPS, basic (₹) | 5.04 | — | — | — | — |
| Net margin (%) | 15.9 | — | — |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 9.59 | — | — | — | — |
| Other income | 7.19 | — | — | — | — |
| Total income | 16.78 | — | — | — | — |
| Profit before tax | 1.32 | — | — | — | — |
| Net profit for the period | 1.07 | — | — | — | — |
| EPS, basic (₹) | 0.32 | — | — | — | — |
| Net margin (%) | 11.2 | — | — |
Consolidated
- Filed with BSE
- 24 Jan 2025, 12:41 IST
- Board meeting
- 23 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jan 2025, 12:41 IST
- Board meeting
- 23 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE